High-Purity EPA Ethyl Ester for Hypertriglyceridemia Without LDL-C Rise
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, such as hypertriglyceridemia, often result in undesirable elevations of LDL-C and non-HDL-C levels, and there is a need for improved lipid-regulating agents that can effectively reduce triglycerides without these adverse effects.
Innovation Solution
A pharmaceutical composition comprising eicosapentaenoic acid ethyl ester (EPA-E) is administered, which contains substantially no docosahexaenoic acid (DHA) and is formulated to have a high EPA content, typically at least 96% by weight, to treat moderate to severe hypertriglyceridemia, reducing triglyceride levels and improving lipid profiles without increasing LDL-C and non-HDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments like Lovaza are used to treat hypertriglyceridemia, then some triglyceride reduction is achieved, but the reduction is insufficient and lipid profiles are not adequately improved
Solution Approach 1:
The patent changes the chemical composition parameters by using highly purified eicosapentaenoic acid ethyl ester with at least 96% purity and specifically controlling the ratio of EPA to DHA (at least 4:1), which resolves the insufficiency of existing treatments in achieving adequate triglyceride reduction and lipid profile improvement
2Adaptability or versatility
If docosahexaenoic acid derivatives are included in the composition, then the product has broader fatty acid coverage, but the purity of eicosapentaenoic acid is reduced and treatment efficacy is compromised
Solution Approach 1:
The patent extracts and isolates only the necessary eicosapentaenoic acid ethyl ester component from the complex mixture of fatty acids, removing docosahexaenoic acid and other unnecessary components. This extraction achieves at least 96% EPA purity while maintaining treatment efficacy for hypertriglyceridemia
Data Source
AI summary
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.